Reference

Last reviewed: 28 Apr 2026
Sources cited: 9
Residues: 3

Primary structure3 residues · 342.4 Da

01LysLysine

02ProProline

03ValValine

Nonpolar Polar Acidic Basic Aromatic Gly/Pro

KPV

Last verified: 2026-04-24

At a glance


Also known as	Lys-Pro-Val, α-MSH(11-13), KPV tripeptide
Class	Synthetic tripeptide, C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH)
Typical route	Oral (capsule or sublingual), subcutaneous injection, topical, intranasal
Plasma half-life	Less than 30 minutes (short systemic half-life due to proteolytic degradation); biological half-life within tissues may be longer
Duration of effect	Anti-inflammatory effects persist at tissue level past plasma clearance
Molecular weight	342.4 Da
Sequence	Lys-Pro-Val (3 amino acids — the smallest peptide in this encyclopedia)

What it is

KPV is a three-amino-acid fragment of α-melanocyte-stimulating hormone (α-MSH) — specifically its C-terminal tripeptide. Despite being tiny, it is the functional anti-inflammatory core of the parent hormone: most of α-MSH’s anti-inflammatory activity is attributable to this sequence alone.

Unlike most peptides, KPV has two features that make it genuinely unusual in this space:

It’s orally bioavailable. KPV is small enough to be transported intact across the gut lining by the PepT1 transporter — a membrane protein that normally carries dietary di- and tripeptides into intestinal cells. This is the same mechanistic quirk that makes BPC-157 orally viable, but KPV is even smaller and even better-suited to PepT1 transport.
Its mechanism is uncharacteristically clean. KPV directly inhibits NF-κB, the master transcription factor that orchestrates almost every inflammatory cascade in the body. This is one of the most-studied anti-inflammatory mechanisms in medicine, and KPV activates it without touching the melanocortin receptor system that α-MSH normally binds to.

It’s used primarily for gut inflammation (IBD, IBS, ulcerative colitis, leaky gut), skin inflammation (atopic dermatitis, psoriasis-adjacent conditions), and mast cell / histamine reactivity. It’s the most mechanistically-targeted anti-inflammatory peptide in the biohacker space, and the one with the most direct relevance to the Rest Reclaimed audience.

Mechanism

KPV’s pharmacology is unusually well-characterised for a biohacker-space peptide.

PepT1-mediated transport. KPV enters cells (particularly intestinal epithelial cells) via the hPepT1 peptide transporter. This is the mechanism that makes oral dosing viable and explains the compound’s preferential effects in the gut lining.1
Direct NF-κB inhibition. Once inside the cell, KPV suppresses NF-κB activation — blocking the master inflammatory transcription factor. Downstream effects include reduced IL-8 secretion, reduced TNF-α production, and dampening of the MAPK inflammatory signalling cascade.2
Mast cell activity modulation. α-MSH and its KPV fragment reduce mast cell activation and degranulation in multiple models. Mechanism is partly NF-κB-mediated; additional pathways may involve direct mast cell membrane effects.
Antimicrobial activity. KPV exhibits activity against Staphylococcus aureus, Candida albicans, and other pathogens — likely contributing to its skin and wound-healing applications.3
No melanocortin receptor binding. Critically, KPV does not bind to MC1R, MC3R, or MC5R (the receptors α-MSH normally acts through). Its anti-inflammatory effect is PepT1-mediated, not receptor-mediated. This distinguishes it from α-MSH itself, which can cause melanogenesis (skin darkening) and other off-target effects via receptor binding. KPV skips those entirely.

The combination of PepT1 transport + NF-κB inhibition + no receptor binding produces an unusually targeted mechanism: it reaches inflamed gut tissue via a specific transporter, acts on a central inflammatory pathway, and doesn’t trigger the hormonal side effects of its parent peptide.

Routes of administration

KPV is the compound in this encyclopedia with the widest viable route profile. Each route has a distinct use-case.

Oral (capsule or sublingual)


Bioavailability	Genuinely viable via PepT1 transport — one of the few peptides with meaningful oral bioavailability. Exact percentage not formally quantified in humans.
Onset	30–90 minutes for systemic effect; gut-targeted effect likely faster
Duration	Anti-inflammatory effect persists beyond short plasma half-life
Typical dose (this route)	200–500 mcg/day
Equipment	Pre-made capsules, liquid drops, or sublingual troches
When this route makes sense	Gut inflammation, IBD, IBS, leaky gut, colitis, Crohn’s-adjacent symptoms. This is KPV’s strongest use-case. The compound reaches inflamed gut tissue directly.

The default and most evidence-supported route. For gut-focused use, oral is not just convenient — it’s mechanistically correct. KPV acts locally on gut epithelium via PepT1 transport before systemic absorption matters. Typically taken on an empty stomach, 30–60 minutes before a meal, to maximise gut-lining exposure.

Subcutaneous injection


Bioavailability	Standard subQ absorption — high systemic availability
Onset	15–45 minutes for systemic effect
Duration	Short plasma presence; biological effects persist
Typical dose (this route)	200–500 mcg/day
Equipment	Insulin syringe, BAC water, alcohol wipes
When this route makes sense	Systemic inflammation, skin conditions requiring systemic delivery, MCAS without predominant gut involvement. Higher systemic exposure than oral for non-gut targets.

Used when gut isn’t the primary target. Systemic subQ for generalised anti-inflammatory effect, MCAS with whole-body reactivity, autoimmune-adjacent systemic inflammation.

Topical


Bioavailability	Poor passive skin penetration. KPV does not readily cross intact skin barrier without specialised delivery systems.
Onset	Variable; largely depends on formulation
Typical dose (this route)	Highly variable; often used in ~0.1% creams/serums but effective concentration for skin penetration is unclear
When this route makes sense	Direct application to open wounds, compromised skin barriers, inflamed skin lesions where the barrier is already disrupted. Intact-skin topical application has limited evidence.

Honest caveat: topical KPV is widely marketed for skin conditions, but the skin-barrier penetration problem is real. Topical use on intact skin (general anti-ageing, pigmentation) is much weaker evidentially than use on damaged skin (wounds, ulcers, active eczema lesions). Properly-formulated delivery systems (liposomes, nanoparticles) can partly solve this; over-the-counter creams often cannot.

Intranasal


Bioavailability	Not formally studied in humans for KPV specifically. Extrapolated from general peptide nasal delivery.
Onset	15–45 minutes
Duration	Short plasma presence
Typical dose (this route)	200–500 mcg/day
Equipment	0.1% nasal solution
When this route makes sense	Sinus inflammation, upper-respiratory inflammation, rhinitis. Not a primary use-case but emerging in community protocols.

Less evidence-supported than oral or subQ. Used for sinus/nasal inflammation by extrapolation from the compound’s general anti-inflammatory mechanism. Community adoption is ahead of published research here.

Cross-route comparison

Use-case	Best route	Why
Gut inflammation (IBD, IBS, leaky gut)	Oral	PepT1 transport delivers directly to gut lining
Systemic inflammation / MCAS	SubQ	Reliable systemic delivery
Wound healing / active skin lesions	Topical (or subQ adjunct)	Direct local effect where barrier is disrupted
Intact-skin cosmetic/anti-ageing use	Subcutaneous preferred	Topical penetration too poor to rely on
Sinus / respiratory inflammation	Intranasal	Local delivery, less evidence

Multi-route combinations are common. Users with gut + skin inflammation sometimes run oral KPV for gut effect plus topical for local skin lesions, with subQ reserved for flares. The compound is cheap enough at research-chemical prices that combination routes are practical.

What the evidence says

Honest summary: genuinely well-characterised mechanistically for a biohacker peptide. Strong preclinical base. Human clinical data limited to small pilot-scale studies.

Preclinical (strong):

Ulcerative colitis in mice (2017) — HA-functionalised nanoparticle-delivered KPV at 16 μg/kg/day for 5 days in DSS-induced colitis. Body weight recovery, TNF-α expression comparable to healthy controls, colon histology near-normal.4 Important caveat: this used specialised nanoparticle delivery, not plain oral KPV, though the pharmacology predicts direct oral dosing should work via PepT1 in the inflamed gut.
Multiple animal models of: allergic and irritant contact dermatitis, cutaneous vasculitis, asthma, inflammatory bowel disease, rheumatoid arthritis, ocular inflammation, brain inflammation. Consistent anti-inflammatory signal across models.5
PepT1-mediated gut transport formally characterised in intestinal cell models.1
Longest continuous animal dosing study: 12-week murine colitis model with no cumulative toxicity, organ dysfunction, or behavioural changes observed.

Human clinical:

No large randomised trials. No completed Phase 2 or 3 studies.
KPV is scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) consultation on 23 July 2026 — one of seven peptides being considered for 503A Category 1 inclusion. This is significant because PCAC consideration implies the FDA believes there’s enough human-relevance data to warrant a pathway discussion.6
Small pilot use in functional and integrative medicine for IBD, MCAS, and skin inflammation. No controlled data.

Community evidence:

Strongly positive user reports for gut conditions. Users with IBS, IBD-spectrum symptoms, food intolerance, and leaky gut frequently report meaningful symptom reduction within 1–2 weeks.
MCAS community reports describe KPV as among the more tolerable peptides, particularly useful for smoothing the introduction of other compounds (BPC-157, TB-500) that can initially flare mast cells.
Skin condition reports are more mixed — strong results for inflammatory flares (eczema, active lesions), weaker for general skin quality or intact-skin cosmetic use.

Typical use patterns

Observations, not recommendations.

Dose:

Oral (gut-focused): 200–500 mcg/day, often starting at 200 mcg for week one and titrating up
SubQ (systemic): 200–500 mcg/day
Topical: typically 0.1% formulation, applied once or twice daily to affected areas
Intranasal: 200–500 mcg/day, usually split into two doses

Timing:

Oral: empty stomach, 30–60 min before a meal (maximises gut-lining exposure before food dilution)
SubQ: flexible, often morning
Topical: after cleansing, before moisturiser
All routes well-tolerated at any time of day — no stimulating or sedating effects to time around

Cycle:

Typical: 4–8 weeks on, 2–4 weeks off
For acute gut flares: shorter courses (2–4 weeks) concentrated around the flare
For chronic conditions (IBD maintenance, chronic MCAS): longer cycles with shorter breaks are common in community practice, though beyond 12 weeks continuous is uncharacterised in literature

Stacking:

BPC-157 + KPV is the canonical gut-healing stack. KPV for immediate inflammation reduction, BPC-157 for longer-arc tissue repair.
KPV before starting BPC-157, TB-500, or other angiogenic/repair peptides in MCAS users — this is one of the few peptide stack patterns with a real rationale: KPV’s mast cell calming effect can reduce the initial flare risk when introducing compounds that provoke sensitive immune systems.
KPV + cromolyn sodium / ketotifen for MCAS users already on mast-cell stabilising medication — additive anti-inflammatory effect with different mechanisms
Compatible with most other peptide stacks; no known significant interactions

For sensitive systems

KPV may be the single most sensitive-systems-friendly peptide in this encyclopedia. It’s why we flag it repeatedly on other compound pages.

Why KPV fits this audience:

Direct anti-inflammatory mechanism via NF-κB — the same pathway implicated in most chronic inflammatory conditions including MCAS, long COVID, autoimmune, and IBD
Mast cell activity reduction without the repair-activity-triggered flares that BPC-157 and TB-500 can cause
No histamine-provoking mechanism — unlike peptides that drive tissue turnover and mobilise mast cells, KPV actively suppresses mast cell activation
Oral bioavailability means no injection is required, which matters for needle-averse or injection-reactive users
Mechanism overlaps with conventional MCAS treatment (cromolyn, ketotifen) rather than competing with it — can be layered reasonably safely

Start dose. 100–200 mcg/day oral for 5–7 days. This is half or less of typical community dose.

Ramp. If tolerated, increase to 200–400 mcg/day. Many sensitive users plateau at 200–300 mcg/day and don’t need higher doses.

Expected adjustment profile:

Mild transient fatigue — occasionally reported in the first few days, likely related to rapid inflammation reduction changing baseline state
Bowel habit changes (mild, transient) — softer or looser stools in first week as gut inflammation reduces; typically settles
Skin changes — in users with chronic skin inflammation, some describe a brief worsening or “flare before settling” pattern, similar to retinoid purging but usually milder
No documented mast cell provocation — this is a mast cell suppressor, not a trigger
No documented histamine flare profile — the opposite of BPC-157’s initial pattern

What’s not normal and warrants stopping: severe GI symptoms (bloody stool, persistent diarrhoea, severe cramping beyond first week), new systemic allergic-type reactions, significant mood changes.

What to have on hand:

Nothing specific. KPV is one of the lower-maintenance peptides for sensitive users.
If using oral: enteric-coated or sublingual forms may improve gut delivery for some users

Interactions worth considering:

Cromolyn sodium, ketotifen, mast cell stabilisers: complementary mechanism, commonly stacked
LDN (Low Dose Naltrexone): no documented interaction; different mechanism; commonly used together in MCAS practice
Conventional IBD medications (mesalazine, sulfasalazine, biologics): no documented direct interaction. Some users report KPV allowing reduction of other medications, but this is anecdotal and should not be attempted without medical oversight
Antihistamines (H1/H2): no interaction; commonly combined
Corticosteroids: mechanism overlap (both anti-inflammatory, different pathways); additive effect likely
Antibiotics: no interaction; in fact KPV’s antimicrobial activity against S. aureus and C. albicans may be complementary for certain infections

PMDD note: PMDD has inflammatory and HPA-axis components; KPV’s anti-inflammatory mechanism is mechanistically plausible for relevance but unstudied. Worth tracking. Not a primary PMDD intervention.

Long COVID / ME/CFS note: these populations often have elevated inflammatory markers, gut dysbiosis, and mast cell involvement. KPV addresses all three mechanistically. Anecdotal reports in these populations are positive but uncontrolled. One of the more defensible peptides to consider for self-directed trial.

Reasonable expectations

Onset. Acute anti-inflammatory effects can be subjective within 3–7 days for gut-focused use. Skin effects are slower — 2–4 weeks typical for meaningful change. Systemic inflammation markers (if you’re tracking them) may show measurable change in 2–6 weeks.

Response rate. Higher than most biohacker peptides. Community estimates suggest 70–80% of users report clear benefit for gut-focused use. Skin and systemic use response rates are lower, ~50–60%.

What the literature actually supports.

Anti-inflammatory effect via NF-κB inhibition: strongly supported mechanistically, well-replicated in cell and animal models
Gut-targeted efficacy via PepT1 transport: supported by pharmacology and animal colitis models
Mast cell activity modulation: reasonable mechanistic support, limited human data
Antimicrobial activity: demonstrated in lab settings
Wound healing: positive signal in animal models

What not to expect.

A substitute for IBD medications (mesalazine, biologics) in active disease. KPV can complement; it cannot replace.
Dramatic results for intact-skin cosmetic use. Topical penetration is too poor and systemic effect too subtle.
Rapid relief of severe active flares. KPV is better positioned as a maintenance and flare-prevention tool than an acute rescue.
A complete MCAS solution. It’s one useful tool in a multi-modal approach, not a single-intervention answer.
Equivalent evidence to pharmaceutical anti-inflammatories. The mechanism is real; the clinical trial base is still developing.

Cost

Approximate as of April 2026, research-chemical market, UK-focused. Vendor-neutral.


10 mg lyophilised vial (injectable-grade)	£30–55
Oral capsules (500 mcg × 60)	£45–80 per bottle
Sublingual troches (250 mcg × 30)	£35–65
0.1% topical cream (30 mL)	£30–60
Cost per month, community-standard oral (400 mcg/day)	~£25–45
Cost per month, sensitive-start oral (200 mcg/day)	~£15–25
Cost per month, subQ (400 mcg/day)	~£20–35

KPV is moderately priced. Oral capsules cost significantly more than reconstituting injectable and converting to sublingual, but are more convenient. Bulk (10 mg vials) reconstituted for both injection and oral sublingual use is the most cost-effective approach for users running multiple routes.

Reconstitution

10 mg lyophilised KPV:

Reconstitute in 2 mL bacteriostatic water → 5 mg/mL (5,000 mcg/mL)
200 mcg dose = 0.04 mL = 4 IU on a U-100 insulin syringe
500 mcg dose = 0.1 mL = 10 IU

For oral/sublingual use from injectable vial:

Same reconstitution; drawn into an oral-use dropper instead of syringe
Taken on empty stomach, held under tongue for 60–90 seconds if sublingual, or swallowed directly

For topical use:

Typically requires formulation with a carrier (purpose-made liposomal cream, DMSO-based carrier, or commercial peptide carrier)
User-reconstitution for topical is inadvisable without understanding of formulation chemistry — preservation, stability, and skin penetration are all formulation-dependent

Open the Vial Plan calculator

Reconstituted KPV is stable in BAC water, refrigerated, for ~30 days. Lyophilised KPV is stable at room temperature for months.

Areas of concern ⚠

Safety signals

Genuinely low-signal safety profile. Across animal models and community use, KPV has one of the cleanest adverse event profiles of any peptide in this encyclopedia.
No serious adverse events, dose-limiting toxicity, or organ dysfunction documented in peer-reviewed studies as of 2026.
Common side effects are mild: injection site reactions (8–12%), mild nausea (3–5%), transient skin irritation or GI upset with topical or oral use.

Long-term safety is uncharacterised

12 weeks is the longest published continuous dosing study, and that’s in mice. Human long-term safety beyond ~3 months is unknown.
Daily dosing protocols extending past 12 weeks operate in uncharted territory. Community protocols routinely do this; users doing so should be aware.

PepT1 transporter variability

The oral bioavailability mechanism depends on functional PepT1 transporter expression in the gut lining.
In severe IBD or extensive gut damage, PepT1 function may be impaired — which is paradoxical because these are the users most likely to want KPV for gut benefit. Not a contraindication but a reason some users report weaker response than expected in advanced disease.
PepT1 expression varies across the gut (highest in small intestine, lower in colon) — affecting where in the GI tract KPV exerts its effects.

Topical claims vs topical reality

Commercial KPV topical products (serums, creams) are widely sold. Their efficacy on intact skin is likely over-claimed.
Properly-formulated delivery systems (liposomes, penetration enhancers) can help; generic “KPV cream” mixed from research powder is unlikely to penetrate well.
For wound or ulcer application where the barrier is already disrupted, topical is more defensible.

Quality and sourcing

Research-chemical KPV is widely available and relatively cheap. Purity varies.
Oral formulations (capsules, troches) introduce additional quality-control issues beyond raw peptide — fillers, coatings, and preservatives all affect tolerability
Storage: lyophilised is stable at room temperature; reconstituted solution should be refrigerated, used within 30 days

Populations where caution is warranted

Active malignancy — no specific mechanism for concern, but NF-κB inhibition is immunomodulatory and the systemic effects in cancer contexts are not studied
Pregnancy and breastfeeding — no human data, default contraindication
Severe immunosuppression — theoretical concern about adding further anti-inflammatory pressure to an already-suppressed immune system
Active GI bleeding or severe IBD flare — not a reason to avoid KPV specifically, but self-directed peptide use during acute severe disease should not replace medical care
Under 18 — no data

Regulatory signal (not quite a concern, but worth knowing)

KPV being scheduled for FDA PCAC review in July 2026 signals the compound is being formally evaluated, which is good from a safety-of-the-pipeline perspective
It also means the regulatory status could change meaningfully in late 2026. A Category 1 listing would open the compounding pathway in the US; a rejection would signal formal concern about something. Worth tracking.

FDA / regulatory status

Jurisdiction	Status	Last verified
US (FDA)	Scheduled for PCAC consultation 23 July 2026 for potential 503A Category 1 inclusion. Not currently approved. Recently removed from Category 2 (April 2026 update).	2026-04-24
UK (MHRA)	Not licensed. Not a controlled substance. Sold as research chemical with “not for human consumption” labelling.	2026-04-24
EU (EMA)	Not approved. Similar posture to UK.	2026-04-24
WADA (sport)	Not explicitly listed. Treat as prohibited for tested athletes under general peptide/hormone category.	2026-04-24

Narrative. KPV has the most active regulatory story of any peptide in this encyclopedia. The July 2026 PCAC consultation is a live event — the Pharmacy Compounding Advisory Committee will formally evaluate whether KPV (free base and acetate forms) should be included on the 503A Category 1 Bulks List. A positive outcome would restore legal compounded access in the US through licensed pharmacies; a negative outcome would signal formal safety concern. Either way, the current “research chemical only” status in the US is likely to change meaningfully in late 2026 or 2027.

For UK readers: KPV is legally available as a research chemical from UK-based suppliers. Not a controlled substance. Personal possession is not an offence. Sale for human consumption is not permitted.

What to track in Peptrax

KPV is the encyclopedia’s most explicit sensitive-systems compound, and the people taking it usually have a specific symptom pattern they want to move — gut inflammation, MCAS flares, skin reactivity, autoimmune-adjacent symptoms. The signal worth capturing is symptom-specific and daily: GI symptoms post-meal, flushing or histamine episodes, skin reactivity, energy floor. A generic “felt better” rating misses what’s actually changing, because the patterns these users care about are textured rather than uniform.

The on-cycle vs off-cycle contrast is the most honest readout. Two-to-four week cycles are typical, and tracking what comes back when KPV stops is genuinely informative — if symptoms drift up over the off-week, that is the answer. Logging cycle dates, route (oral capsule and subQ are both common, with very different absorption profiles), and dose lets that retrospective work.

For users pairing KPV with BPC-157 (the common MCAS pattern), the attribution problem is real. Logging which compound was active when, and whether either was added during a flare, lets a later reflection separate the signals. KPV is also the compound where stop criteria matter most — any escalating reaction, new GI symptoms, or breathing changes mean stop and reassess, not push through. Writing those criteria down before starting a cycle is more useful than reconstructing them mid-flare.

For personal tracking and informational purposes only — not medical advice.

KPV